# Epirubicin

## Epicin 10mg/5mL

##### 

| TAH Drug Code      | [IEP10](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEP10)                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Leukemia, lymphoma, breast cancer, sarcomas, small-cell lung carcinoma, ovarian cancer, gastric cancer. Liver cancer, head & neck cancer, pancreatic cancer.                                                                                                                                                                                         |
| Dosing             | (仿單) Epirubicin should be administered intravenously or intravesicularly. Do not administer epirubicin orally, intramuscularly or subcutaneously. A lifetime maximum cumulative dose >1000 mg/m2 should be avoided. Usual dose: 75-90 mg/m2 intravenously once every 3 weeks. Intravesicular: 50 mg once weekly for 8 weeks; dose range: 30-80 mg. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Myelosuppression. Cardiac impairment. Previous full cumulative doses of anthracyclines. Pregnancy. Lactation.                                                                                                                                                                                                                                        |
| Adverse Effects    | Myelosuppression, cardiotoxicity, alopecia, mucositis, GI disturbances, hyperpyrexia.                                                                                                                                                                                                                                                                |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                      |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                      |

## EPICIN 50mg/25mL

##### 

| TAH Drug Code      | [IEP50](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEP50)                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Leukemia, lymphoma, breast cancer, sarcomas, small-cell lung carcinoma, ovarian cancer, gastric cancer. Liver cancer, head & neck cancer, pancreatic cancer.                                                                                                                                                                                         |
| Dosing             | (仿單) Epirubicin should be administered intravenously or intravesicularly. Do not administer epirubicin orally, intramuscularly or subcutaneously. A lifetime maximum cumulative dose >1000 mg/m2 should be avoided. Usual dose: 75-90 mg/m2 intravenously once every 3 weeks. Intravesicular: 50 mg once weekly for 8 weeks; dose range: 30-80 mg. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Myelosuppression. Cardiac impairment. Previous full cumulative doses of anthracyclines. Pregnancy. Lactation.                                                                                                                                                                                                                                        |
| Adverse Effects    | Myelosuppression, cardiotoxicity, alopecia, mucositis, GI disturbances, hyperpyrexia.                                                                                                                                                                                                                                                                |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                      |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                      |

